[Changes in serum levels of resistin and visfatin in pediatric patients with acute Kawasaki disease following intravenous immune globulin treatment].
OBJECTIVE
To determine serum levels of resistin and visfatin in the patients with acute Kawasaki disease before and after intravenous immune globulin (IVIG) treatment.


METHODS
A total of 50 children with acute Kawasaki disease were treated with IVIG for 48 hours between January 2011 and January 2013. As controls, 30 healthy children and 30 children with acute infectious diseases were included. Serum levels of resistin and visfatin were measured by ELISA both before and after the treatment.


RESULTS
The baseline serum levels of resistin and visfatin were significantly higher in patients with acute Kawasaki disease than in the two control groups of subjects (i.e., healthy children and patients with acute infectious diseases; P<0.05). In the 50 patients with Kawasaki disease, 38 were not responding and 12 were responding. Serum resistin levels before treatment were significantly higher in non-responders than those in responders (P<0.05). A significant decrease in serum levels of resistin after treatment was observed in IVIG responders (P<0.05). Serum visfatin levels were not significantly different between IVIG responders and non-responders (P>0.05). Additionally, serum resistin and visfatin levels were not significantly different between acute Kawasaki disease patients with and without coronary artery lesions.


CONCLUSIONS
Resistin and visfatin may play important roles in the development of Kawasaki disease and serum resistin may be used as a novel outcome indicator of the IVIG treatment.
Department of Pediatrics, China Three Gorges University People's Hospital, Yichang, Hubei 443000, China. shufang_fu@163.com.
Shu-Fang
SF
Fu
Da-Liang
DL
Yu
Dian-Yi
DY
Lv
Feng-Yi
FY
Chen
D000208:Acute Disease; D002675:Child, Preschool; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000097:blood / Q000188:drug therapy*; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D052243:Resistin / Q000097:blood*
D016207:Cytokines; D016756:Immunoglobulins, Intravenous; C499624:RETN protein, human; D052243:Resistin; D054409:Nicotinamide Phosphoribosyltransferase; C085455:nicotinamide phosphoribosyltransferase, human